Pancreatic ductal adenocarcinoma (PDAC) is a painful, deadly, and incurable disease for which effective treatments remain to be discovered and tested. The OVERALL OBJECTIVES of this study are to define mechanisms underlying the regulation of PDAC cell growth, by focusing on further characterizing a novel pathway for which individual components can be targeted pharmacologically. Previous studies along with our preliminary data indicate that mitotic aberrations and PDAC cell growth, two highly interrelated processes, rely on signaling from Aurora A (AurkA) to the HP1?-G9a pathway. Mutations or aberrant expression of either AurkA or the HP1? -G9a complex are implicated in the development of neoplasms of different origins, including PDAC. We will test the CENTRAL HYPOTHESIS that a novel AurkA-HP1?-G9a pathway regulates mitotic progression and PDAC cell growth in a manner amenable to pharmacological inhibition using combination therapy. Congruently, our SPECIFIC AIMS are: 1. To characterize the function of the HP1?-G9a complex as a downstream mediator of the effects of AurkA on mitotic progression in PDAC cells;2. To characterize cellular and molecular mechanisms that contribute to the inhibitory effects of the AurkA-HP1?-G9a pathway on PDAC growth;and 3. To characterize the effects of combined targeting of the AurkA-HP1?-G9a pathway on PDAC progression in orthotopic xenografts and genetically engineered mice models. Thus, our research will span from the level of molecules to cell populations to the whole organism. These studies are feasible for our laboratory, which has developed the appropriate conceptual framework, reagents, trained personnel and established collaborations to execute the proposed research. The design of this proposal is innovative as it seeks to maximize the yield of new mechanistic knowledge and pharmacological interventions, which impact on PDAC tumor growth. Since PDAC is a dismal disease, the discovery and proposed study of this novel AurkA-HP1?-G9a pathway bears significant biomedical relevance.

Public Health Relevance

These investigations represent a defined strategy to discover novel therapeutic approaches for pancreatic ductal adenocarcinoma, a painful and deadly disease that ranks 4th in USA cancer deaths, for which no effective treatment currently exists. We propose to investigate a pathway that regulates pancreatic cancer cell division and growth in a manner that can be exploited by combined therapies for the ultimate goal of treating this dismal disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA178627-01A1
Application #
8753391
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Hildesheim, Jeffrey
Project Start
2014-08-01
Project End
2019-07-31
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$329,925
Indirect Cost
$122,425
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Loncle, C; Molejon, M I; Lac, S et al. (2016) The pancreatitis-associated protein VMP1, a key regulator of inducible autophagy, promotes Kras(G12D)-mediated pancreatic cancer initiation. Cell Death Dis 7:e2295
Lomberk, Gwen A; Iovanna, Juan; Urrutia, Raul (2016) The promise of epigenomic therapeutics in pancreatic cancer. Epigenomics 8:831-42
Velez, Gabriel; Lin, Marisa; Christensen, Trace et al. (2016) Evidence supporting a critical contribution of intrinsically disordered regions to the biochemical behavior of full-length human HP1γ. J Mol Model 22:12
Leonard, Phoebe H; Grzenda, Adrienne; Mathison, Angela et al. (2015) The Aurora A-HP1γ pathway regulates gene expression and mitosis in cells from the sperm lineage. BMC Dev Biol 15:23
Lomberk, Gwen A; Urrutia, Raul (2015) The Triple-Code Model for Pancreatic Cancer: Cross Talk Among Genetics, Epigenetics, and Nuclear Structure. Surg Clin North Am 95:935-52
Guo, Yanhong; Fan, Yanbo; Zhang, Jifeng et al. (2015) Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest 125:3819-30
Papadakis, Konstantinos A; Krempski, James; Svingen, Phyllis et al. (2015) Krüppel-like factor KLF10 deficiency predisposes to colitis through colonic macrophage dysregulation. Am J Physiol Gastrointest Liver Physiol 309:G900-9
Grasso, Daniel; Bintz, Jennifer; Lomberk, Gwen et al. (2015) Pivotal Role of the Chromatin Protein Nupr1 in Kras-Induced Senescence and Transformation. Sci Rep 5:17549
Mathison, Angela; Escande, Carlos; Calvo, Ezequiel et al. (2015) Phenotypic Characterization of Mice Carrying Homozygous Deletion of KLF11, a Gene in Which Mutations Cause Human Neonatal and MODY VII Diabetes. Endocrinology 156:3581-95
Lopez, Maria Belen; Garcia, Maria Noé; Grasso, Daniel et al. (2015) Functional Characterization of Nupr1L, A Novel p53-Regulated Isoform of the High-Mobility Group (HMG)-Related Protumoral Protein Nupr1. J Cell Physiol 230:2936-50

Showing the most recent 10 out of 16 publications